Samsara Becomes First Highway Certified ELD Provider Ascendis Pharma A/S Announces Share Repurchase Program
COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical…
Mountain Valley MD Holdings Provides Business Update, Results of Shareholder Meeting
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference
EMERYVILLE, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage…
BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th
ANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”),…
Agenda and draft decisions of the extraordinary shareholders’ meeting of joint stock company “Olainfarm”
Management board of the joint stock company “Olainfarm”, registration No 40003007246, registered address: Rūpnīcu iela…
Guerbet: Guerbet contributes to the NH TherAguix IPO on Euronext Growth, a specialist in innovative biotechnologies for precision radiotherapy
Guerbet contributes to the NH TherAguix IPO on Euronext Growth, a specialist in innovative biotechnologies…
PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
PAOG CBD Nutraceutical Launch Timed To Capture Market Momentum
Sandusky, OH, Sept. 29, 2021 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) has…
The Consortium for Top-Down Proteomics Launches a New Initiative to Develop the Human Proteoform Atlas
The project will engage the community to build the definitive reference set of the human…
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo…
Rentschler Biopharma Inc. Recognized by Massachusetts House of Representatives as Manufacturer of the Year for District
Company honored at 6th Annual Massachusetts Legislative Manufacturing Caucus Awards ceremony LAUPHEIM, Germany and MILFORD,…
All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431
EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
Denali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343 Sanofi…
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
No serious adverse events or dose-limiting toxicities observed to date Efficacy signals in the mid-dose…
TNFα-supplemented DL-4 culture system supports first-in-clinic Smart Immune ProTcell™ technology for immuno-deficient patients fighting cancers and infections
Rapid reset of immune system can provide marked benefits in clinical settings where patients are…
Mountain Valley MD Holdings Announces Letter of Intent with Red White and Bloom Brands Inc.
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
Enlivex to Present at Reuters Events’ Cell & Gene Therapy USA 2021
Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021
MONTREAL, Sept. 29, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a…
SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp
Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against…
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint…